Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

234 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Resolution of pansclerotic morphea after treatment with antithymocyte globulin.
Song P, Gocke C, Wigley FM, Boin F. Song P, et al. Among authors: wigley fm. Nat Rev Rheumatol. 2009 Sep;5(9):513-6. doi: 10.1038/nrrheum.2009.159. Nat Rev Rheumatol. 2009. PMID: 19710673
Targeting mediators of vascular injury in scleroderma.
Schachna L, Wigley FM. Schachna L, et al. Among authors: wigley fm. Curr Opin Rheumatol. 2002 Nov;14(6):686-93. doi: 10.1097/00002281-200211000-00010. Curr Opin Rheumatol. 2002. PMID: 12410092 Review.
Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation.
Macko RF, Gelber AC, Young BA, Lowitt MH, White B, Wigley FM, Goldblum SE. Macko RF, et al. Among authors: wigley fm. J Rheumatol. 2002 Dec;29(12):2565-70. J Rheumatol. 2002. PMID: 12465153
Treatment of scleroderma: an update.
Sule SD, Wigley FM. Sule SD, et al. Among authors: wigley fm. Expert Opin Investig Drugs. 2003 Mar;12(3):471-82. doi: 10.1517/13543784.12.3.471. Expert Opin Investig Drugs. 2003. PMID: 12605568 Review.
Digital necrosis related to carboplatin and gemcitabine therapy in systemic sclerosis.
Clowse ME, Wigley FM. Clowse ME, et al. Among authors: wigley fm. J Rheumatol. 2003 Jun;30(6):1341-3. J Rheumatol. 2003. PMID: 12784412
Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma.
Hummers LK, Wigley FM. Hummers LK, et al. Among authors: wigley fm. Rheum Dis Clin North Am. 2003 May;29(2):293-313. doi: 10.1016/s0889-857x(03)00019-x. Rheum Dis Clin North Am. 2003. PMID: 12841296 Review.
Scleroderma patients with combined pulmonary hypertension and interstitial lung disease.
Chang B, Wigley FM, White B, Wise RA. Chang B, et al. Among authors: wigley fm. J Rheumatol. 2003 Nov;30(11):2398-405. J Rheumatol. 2003. PMID: 14677184
Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial.
Khanna D, Furst DE, Clements PJ, Park GS, Hays RD, Yoon J, Korn JH, Merkel PA, Rothfield N, Wigley FM, Moreland LW, Silver R, Steen VD, Weisman M, Mayes MD, Collier DH, Medsger TA Jr, Seibold JR; Relaxin Study Group; Scleroderma Clinical Trials Consortium. Khanna D, et al. Among authors: wigley fm. J Rheumatol. 2005 May;32(5):832-40. J Rheumatol. 2005. PMID: 15868618 Clinical Trial.
Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases.
Girgis RE, Mathai SC, Krishnan JA, Wigley FM, Hassoun PM. Girgis RE, et al. Among authors: wigley fm. J Heart Lung Transplant. 2005 Oct;24(10):1626-31. doi: 10.1016/j.healun.2004.12.113. J Heart Lung Transplant. 2005. PMID: 16210140
Understanding, assessing and treating Raynaud's phenomenon.
Boin F, Wigley FM. Boin F, et al. Among authors: wigley fm. Curr Opin Rheumatol. 2005 Nov;17(6):752-60. doi: 10.1097/01.bor.0000179944.35400.6e. Curr Opin Rheumatol. 2005. PMID: 16224254 Review.
234 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback